Symbiotec Pharmalab IPO Details
Issue Date
24 Aug - 27 Aug'26
Price Band
₹938 - ₹988
Lot Size
15 Shares
IPO Size
₹1757 Cr
Listing At
NSE,BSE
Overall Subscription
71.2x
Symbiotec Pharmalab IPO Listing Details
Listing On
1 Sep'26
Issue Price
₹988
Listed Price
₹ 978.2
Retail Gain/Listing Gain
-0.99%Decrease
Schedule of Symbiotec Pharmalab IPO
IPO Open Date
24/08/2026
IPO Close Date
27/08/2026
Basis of Allotment
28/08/2026
Refund Initiation
28/08/2026
Credit of Shares
28/08/2026
Listing on exchange
01/09/2026
Symbiotec Pharmalab IPO Subscription Status Live
(Last updated on 27 Aug 2026 04:45 PM)
Day | Total | QIB | Retail | NII | Employee |
|---|---|---|---|---|---|
Day 1 24-Aug-2026 | 0.74x | 0.35x | 0.88x | 0.91x | 1.32x |
Day 2 25-Aug-2026 | 1.69x | 0.54x | 1.97x | 2.54x | 2.74x |
Day 3 26-Aug-2026 | 5.34x | 0.59x | 5.11x | 12.22x | 5.92x |
Day 4 27-Aug-2026 | 71.05x | 172.03x | 12.58x | 73.54x | 15.07x |
About Symbiotec Pharmalab IPO
The Symbiotec Pharmalab IPO, a mainboard IPO, opens on Monday, August 24, 2026 and closes on Thursday, August 27, 2026. The allotment of shares will take place on Friday, August 28, 2026. The credit of shares to the demat account will take place on Monday, August 31, 2026. The initiation of refunds will take place on Friday, August 28, 2026. The listing of shares will take place on Tuesday, September 1, 2026.
The equity shares offered through the IPO are proposed to be listed on the BSE and the NSE.
The offer consists of both a fresh issue and an offer for sale component. The fresh issue will include 15,21,261 shares aggregating up to ₹150 crore. The offer for sale portion includes 1,62,65,181 shares aggregating up to ₹1,607.00 crore. The total number of shares and aggregate amount are 1,77,86,442 shares aggregating up to ₹1,757crore.
Symbiotec Pharmalab IPO's price band is set at ₹938 to ₹988 per share. The lot size for an application is 15. The minimum amount of investment required by a retail investor is ₹14,820 (15 shares) based on the upper price band.
Symbiotec Pharmalab Limited is a manufacturer of active pharmaceutical ingredients, with a global leadership position in corticosteroid and steroidal-hormone APIs by volume in Fiscal 2026.
Objectives of Symbiotec Pharmalab IPO
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company.
- General corporate purposes.

Don't Miss Symbiotec Pharmalab IPO: Key Details Inside
Kotak Neo
•2m 01s
Symbiotec Pharmalab IPO Valuation
Detail | Information |
|---|---|
Upper Price Band | ₹988 |
Total Issue Size | 1,77,86,442 shares (aggregating up to ₹1,757 crore) |
Total Issue Size | 1,77,86,442 shares (aggregating up to ₹1,757 crore) |
Fresh Issue | 15,21,261 shares (aggregating up to ₹150 crore) |
Offer for Sale | 1,62,65,181 shares (aggregating up to ₹1,607 crore) |
Employee Discount | ₹90 |
EPS Diluted (in ₹) for FY26 | 17.30 |
IPO Lot Size
Application | Lots | Shares | Amount |
|---|---|---|---|
Individual investors (Retail) (Min) | 1 | 15 | ₹14,820 |
Individual investors (Retail) (Max) | 13 | 195 | ₹1,92,660 |
S-HNI (Min) | 14 | 210 | ₹2,07,480 |
S-HNI (Max) | 67 | 1,005 | ₹9,92,940 |
B-HNI (Min) | 68 | 1,020 | ₹10,07,760 |
IPO Share Offer and Subscription Details
Investor Category | Shares Offered |
|---|---|
QIBs | Not more than 50% of the net offer |
Non-institutional Investors (NIIs) | Not less than 15% of the net offer |
Retail-individual Investors (RIIs) | Not less than 35% of the net offer |
Anchor Investor Allocation for Symbiotec Pharmalab IPO
Rank | Anchor Investor | No. of Shares | Anchor Portion (%) | Amount (Cr) |
|---|---|---|---|---|
1 | ICICI Prudential Smallcap Fund | 6,07,290 | 11.40% | 60.00 |
2 | Ashoka Whiteoak ICAV - Ashoka Whiteoak Emerging Markets Equity Fund | 4,55,475 | 8.55% | 45.00 |
3 | Motilal Oswal Small Cap Fund | 4,55,475 | 8.55% | 45.00 |
4 | HDFC Mutual Fund - HDFC Pharma and Healthcare Fund | 4,04,865 | 7.60% | 40.00 |
5 | Mirae Asset Health Care Fund | 3,54,270 | 6.65% | 35.00 |
Note: The above table shows the top five anchor investors in the Symbiotec Pharmalab IPO based on their percentage share of the Anchor Investor portion.
Industry Outlook
Active pharmaceutical ingredients are the primary therapeutic components of a drug. The global API market reached approximately USD 305.5 billion in 2025 and is expected to grow at a 6.8% CAGR, reaching USD 424.6 billion by 2030. Small-molecule APIs represented about 64.3% of market value in 2025, while biological APIs rose from 26.5% in 2020 to 35.7% in 2025. Chronic disease prevalence and demand for generics are driving the volume growth.
Symbiotec operates in a specialised segment. The corticosteroid API market, based on the company's focus products, was valued at USD 421.2 million in 2025 and is estimated to grow at a CAGR of 1.6% to 3.0% between 2025 and 2030. Demand is sustained by respiratory, dermatology, ophthalmology, and inflammatory-disorder applications. Up to 10% of individuals in industrialised countries are now affected by at least one autoimmune condition, which supports continued need for corticosteroid-based treatments.
The CDMO market is projected to grow at a CAGR of 8.2%. India offers structural advantages for contract manufacturing, including lower setup costs, cheaper utilities, and access to affordable raw materials. With one of India's largest industrial-scale fermentation capacities at 700 KL following the commissioning of its Ujjain and Mhow facilities, the company is placed to serve this demand across APIs, fermentation-based products, and complex injectables.
About Symbiotec Pharmalab
Symbiotec Pharmalab Limited manufactures active pharmaceutical ingredients, principally corticosteroid and steroidal-hormone APIs. Its portfolio spans over 60 corticosteroid and steroidal-hormone APIs as of March 31, 2026, across both sterile and non-sterile formats. In Fiscal 2026, the sale of APIs contributed 96.07% of revenue from operations, complex injectables 3.80%, and CDMO services 0.13%. The company held a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs in Fiscal 2026.
Manufacturing is concentrated in Madhya Pradesh. The company operates its Rau and Pithampur facilities and has commissioned the Ujjain and Mhow facilities, giving aggregate capacity of 584.67 MT for chemical synthesis, 700 KL for fermentation, and 20 million vials for complex injectables as of March 31, 2026. The Rau and Pithampur facilities are approved by the US FDA, WHO-GMP, and EU-GMP.
Strengths of Symbiotec Pharmalab
- The company captured over 50% global volume market share in Hydrocortisone, Testosterone and Methylprednisolone in Fiscal 2026, at 80.1%, 76.4% and 76.0%, respectively.
- The company operates a vertically integrated “farm/microbe-to-pharmacy” platform with 700 KL fermentation capacity, supporting in-house sourcing of key starting materials for over 80% of its product portfolio by revenue.
- The company served over 200 customers across more than 40 countries as of March 31, 2026, with an average relationship tenure exceeding ten years for its top five and top ten customers.
- The company is among the first generics players globally to produce double-chamber injectables for Methylprednisolone Sodium Succinate and Hydrocortisone Sodium Succinate, addressing a combined United States market of USD 288 million.
Risks of Symbiotec Pharmalab
- Almost all revenue comes from APIs, which were 96.07% of revenue from operations in Fiscal 2026, so any fall in demand for these products would directly reduce the Company's revenue.
- Export customers outside India generated 67.04% of revenue from operations in Fiscal 2026, exposing the company to currency, trade, and geopolitical risks in foreign markets.
- Revenue from the United States was 13.12% of revenue from operations in Fiscal 2026, so new tariffs or anti-outsourcing legislation there could hurt sales.
- All manufacturing facilities and R&D centres are located in Madhya Pradesh, so any regional disruption could halt production across the Company's operations.
- The facilities are subject to periodic regulatory inspections, and the company received US FDA Form 483 observations after recent inspections, which if unresolved could restrict its ability to export.
Symbiotec Pharmalab Financials
Year | Year Data |
|---|---|
FY26 | 869.15 |
FY25 | 751.55 |
FY24 | 716.25 |
Comparison with peers
Company Name | Revenue from Operations (Cr) | EPS (Diluted) (₹) | NAV per share (₹) | P/E Ratio |
|---|---|---|---|---|
Symbiotec Pharmalab Limited | 869.15 | 19.00 | 184.69 | NA |
Concord Biotech Limited | 1,054.90 | 24.78 | NA | 61.07 |
Divi's Laboratories Limited | 10,560.00 | 96.75 | 631.00 | 87.80 |
Cohance Lifesciences Limited | 2,268.55 | 4.68 | NA | 95.02 |
Laurus Labs Limited | 6,812.90 | 16.45 | NA | 109.36 |
Source: All the financial information for the listed industry peers is on a consolidated basis and is sourced from the filings made with BSE available on www.bseindia.com for the Financial Year ending March 31, 2026.
- P/E Ratio has been computed based on the closing market price of equity shares on August 17, 2026, divided by the diluted EPS.
Anchor Investor Bidding Date
Friday, August 21, 2026
IPO Registrar and Book Running Lead Managers
Registrar Details
MUFG Intime India Private Limited
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Telephone: +91 810 811 4949
Book Running Lead Managers:
- JM Financial Limited
- Avendus Capital Private Limited
- Motilal Oswal Investment Advisors Limited
- Nomura Financial Advisory and Securities (India) Private Limited
Symbiotec Pharmalab Contact Details
385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India.
Email: secretarial@symbiotec.com
Telephone: +91 731 667 6405
Symbiotec Pharmalab Business Model
The company earns its revenue through the manufacture and sale of active pharmaceutical ingredients, chiefly corticosteroid and steroidal-hormone APIs, which contributed 96.07% of revenue from operations in Fiscal 2026. It supplements this with contract development and manufacturing organisation (CDMO) services and a growing complex injectables business, which contributed 0.13% and 3.80% of revenue from operations respectively in Fiscal 2026.
The Company sells to generic and specialty pharmaceutical companies across North America, Europe, and Asia, serving more than 50 domestic and 150 export customers as of March 31, 2026.
Symbiotec Pharmalab Growth Trajectory
Symbiotec Pharmalab's Total Income for FY26 was ₹872.26 crore, whereas in FY25 and FY24 it was ₹755.98 crore and ₹723.33 crore, respectively.
The Profit After Tax for FY26 was ₹109.90 crore, whereas in FY25 and FY24 it was ₹96.79 crore and ₹100.06 crore, respectively.
Their EBITDA for FY26 was ₹231.97 crore, whereas in FY25 and FY24 it was ₹206.11 crore and ₹177.04 crore, respectively.
Symbiotec Pharmalab Market Position
Symbiotec holds a global leadership position in corticosteroid and steroidal-hormone APIs by volume in Fiscal 2026, and is the only Indian and global company present across the top 10 such APIs.
As of 31 March 2026, the company's Total Income, Profit After Tax, and EBITDA were ₹872.26 crore, ₹109.90 crore, and ₹231.97 crore, respectively.
Symbiotec Pharmalab Profit and Loss Statement (in ₹ crore)
Parameter | FY 26 | FY 25 | FY 24 |
|---|---|---|---|
Total Income | 872.26 | 755.98 | 723.33 |
Profit Before Tax | 153.36 | 146.98 | 130.98 |
Profit After Tax | 109.90 | 96.79 | 100.06 |
EPS (Diluted) ₹ | 19.00 | 17.36 | 18.00 |
EBITDA | 231.97 | 206.11 | 177.04 |
Symbiotec Pharmalab Balance Sheet (in ₹ crore)
Parameter | FY 26 | FY 25 | FY 24 |
|---|---|---|---|
Profit Before Tax | 153.36 | 146.98 | 130.98 |
Net Cash from Operating Activities | 174.59 | 47.26 | 187.50 |
Net Cash from Investing Activities | (226.93) | (306.52) | (206.41) |
Net Cash from Financing Activities | 35.99 | 278.16 | 21.85 |
Cash & Cash Equivalents | 10.04 | 26.39 | 7.50 |
Note: () denotes negative
How to apply for Symbiotec Pharmalab IPO?
- Step 1: Log in to your Kotak Neo Demat account to access IPO investments. Next, select the current IPO section.
- Step 2: Specify IPO details. Enter the number of lots and the price you wish to apply for.
- Step 3: Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.
- Step 4: Mandate Notification. Your UPI app will receive a mandate notification to block funds.
- Step 5: Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.
Symbiotec Pharmalab IPO FAQs
The Symbiotec Pharmalab IPO opens for subscription from 24-08-2026 to 27-08-2026, with a total issue size of ₹1757 Cr. The IPO price band is ₹938 to ₹988 per share with a lot size of 15. The company aims to list the shares on BSE & NSE on 01-09-2026.
The Symbiotec Pharmalab IPO will open for subscription on 24-08-2026 and will close on 27-08-2026 for investors.
The minimum lot size for the Symbiotec Pharmalab IPO is 15 equity shares, requiring a minimum investment of ₹14820 for retail investors applying in the IPO.
The price band of the Symbiotec Pharmalab IPO has been fixed at ₹938 to ₹988 per equity share.
You can apply for the Symbiotec Pharmalab IPO online through the Kotak Neo Website or the Kotak Neo App using UPI or ASBA during the IPO subscription period.
Symbiotec Pharmalab IPO allotment will take place on 28-08-2026.
You can check the Symbiotec Pharmalab IPO allotment status online on the registrar’s website or on the NSE and BSE IPO allotment pages using your application number, PAN, or demat account details.
Symbiotec Pharmalab shares will list on the stock exchanges on 01-09-2026.
You can find detailed information about the Symbiotec Pharmalab IPO, including its business operations, financial performance, risk factors, and IPO objectives, in the Draft or Red Herring Prospectus (RHP).
Anil Satwani is the Chairman and Managing Director of Symbiotec Pharmalab Limited.
Related News
This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.
Investments in securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit. The securities are quoted as an example and not as a recommendation. SEBI Registration No-INZ000200137 Member Id NSE-08081; BSE-673; MSE-1024, MCX-56285, NCDEX-1262.










